Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $486000.0.

  • Biodesix's Change in Accured Expenses fell 2186.5% to $486000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 26685.63%. This contributed to the annual value of $1.6 million for FY2024, which is 21910.33% up from last year.
  • Per Biodesix's latest filing, its Change in Accured Expenses stood at $486000.0 for Q3 2025, which was down 2186.5% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Change in Accured Expenses registered a high of $3.3 million during Q2 2023, and its lowest value of -$5.7 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was $191000.0 (2021), whereas its average is -$271736.8.
  • As far as peak fluctuations go, Biodesix's Change in Accured Expenses tumbled by 77024.5% in 2021, and later soared by 289724.77% in 2023.
  • Quarter analysis of 5 years shows Biodesix's Change in Accured Expenses stood at $1.8 million in 2021, then crashed by 106.91% to -$127000.0 in 2022, then soared by 698.43% to $760000.0 in 2023, then soared by 122.89% to $1.7 million in 2024, then crashed by 71.31% to $486000.0 in 2025.
  • Its Change in Accured Expenses was $486000.0 in Q3 2025, compared to $2.3 million in Q2 2025 and -$1.9 million in Q1 2025.